Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17375903 | 0.98 | FUCA1 (0.58) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| Hydrochloric Acid SCHEMBL1816800 | 0.98 | FUCA1 (0.58) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL17304830 | 0.92 | FUCA1 (0.56) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL3604123 | 0.92 | SIGMAR1 (0.65) | FUCA1SIGMAR1ACHECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL17294989 | 0.90 | FUCA1 (0.55) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL5836807 | 0.87 | FUCA1 (0.60) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL7575241 | 0.87 | FUCA1 (0.60) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL19327458 | 0.87 | FUCA1 (0.60) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL7372059 | 0.85 | FUCA1 (0.46) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL42501 | 0.84 | ACHE (0.58) | SIGMAR1ACHECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000063168-A1 | SYNTHESIS OF AZETIDINE DERIVATIVES | COELACANTH CHEMICAL CORPORATION (US) | 2000-10-26 | — | — | WO | claimed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250161307-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-22 | — | — | US | disclosed |
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4469454-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | Janssen Pharmaceutica NV (BE) | 2024-12-04 | — | — | EP | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| CN-112218865-B | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-7759336-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20070167459-A1 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7157471-B2 | Haloalkyl- and piperidine-substituted benzimidazole-derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-02 | — | — | US | disclosed |
| EP-1571146-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-09-07 | — | — | EP | disclosed |
| WO-2000063168-A1 | SYNTHESIS OF AZETIDINE DERIVATIVES | COELACANTH CHEMICAL CORPORATION (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-1999019297-A9 | SYNTHESIS OF AZETIDINE DERIVATIVES | COELACANTH CHEMICAL CORP (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999019297-A1 | SYNTHESIS OF AZETIDINE DERIVATIVES | COELACANTH CHEMICAL CORPORATION (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0215650-B1 | SUBSTITUTED BRIDGED-DIAZABICYCLOALKYL QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | FUCA1 109/4885SIGMAR1 338/4885S1PR1 102/4885 |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | FUCA1 4264/4885SIGMAR1 676/4885S1PR1 901/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | FUCA1 2782/4885SIGMAR1 837/4885S1PR1 3365/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | FUCA1 2782/4885SIGMAR1 837/4885S1PR1 3365/4885 |
| US-20070167459-A1 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | CXCR4, CXCL12, CXCR3 | FUCA1 3593/4885SIGMAR1 339/4885S1PR1 262/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | FUCA1 2782/4885SIGMAR1 837/4885S1PR1 3365/4885 |
| US-20250161307-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | SMOX, SRM, SMS | FUCA1 2730/4885SIGMAR1 1114/4885S1PR1 71/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | FUCA1 2715/4885SIGMAR1 4740/4885S1PR1 3356/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | FUCA1 3314/4885SIGMAR1 4583/4885S1PR1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.